Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov;32(11):1443-1444.
doi: 10.1016/j.annonc.2021.07.012. Epub 2021 Jul 30.

Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients

P Heudel  1 , B Favier  2 , S Assaad  1 , P Zrounba  3 , J-Y Blay  4
Affiliations
Comment

Reduced SARS-CoV-2 infection and death after two doses of COVID-19 vaccines in a series of 1503 cancer patients

P Heudel et al. Ann Oncol. 2021 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors have declared no conflicts of interest.

Figures

Figure 1
Figure 1
Documented SARS-CoV-2 infection and death after one dose versus two doses of COVID-19 vaccines in cancer patients. (A) Risk of SARS-CoV-2 RT-PCR+ from the first vaccine injection (1 dose in blue versus 2 doses in red). (B) Risk of SARS-CoV-2 RT-PCR+ from day-21 after the first vaccine injection (1 dose in blue versus 2 doses in red). (C) Survival from the first vaccine dose (1 dose in blue versus 2 doses in red). (D) Survival from day 21 after the first vaccine dose (1 dose in blue versus 2 doses in red). COVID-19, coronavirus disease; SARS-Co-V2, severe acute respiratory syndrome coronavirus 2.
See this image and copyright information in PMC

Comment on

References

    1. Barrière J., Chamorey E., Adjtoutah Z., et al. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors. Ann Oncol. 2021;32(8):1053–1055. - PMC - PubMed
    1. Assaad S., Avrillon V., Fournier M.-L., et al. High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. Eur J Cancer. 2020;135:251–259. - PMC - PubMed
    1. Solodky M.L., Galvez C., Russias B., et al. Lower detection rates of SARS-COV2 antibodies in cancer patients versus health care workers after symptomatic COVID-19. Ann Oncol. 2020;31(8):1087–1088. - PMC - PubMed
    1. Roeker L.E., Knorr D.A., Thompson M.C., et al. COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia. 2021 doi: 10.1038/s41375-021-01270-w. 1-3. - DOI - PMC - PubMed
    1. Monin L., Laing A.G., Muñoz-Ruiz M., et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021;22(6):765–778. - PMC - PubMed

Substances